📣 VC round data is live. Check it out!

EKF Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for EKF Diagnostics and similar public comparables like Biodesix, Neuronetics, Detection Technology, Airdoc and more.

EKF Diagnostics Overview

About EKF Diagnostics

EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.


Founded

2002

HQ

United Kingdom

Employees

303

Financials (LTM)

Revenue: $71M
EBITDA: $17M

EV

$134M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

EKF Diagnostics Financials

EKF Diagnostics reported last 12-month revenue of $71M and EBITDA of $17M.

In the same LTM period, EKF Diagnostics generated $36M in gross profit, $17M in EBITDA, and $5M in net income.

Revenue (LTM)


EKF Diagnostics P&L

In the most recent fiscal year, EKF Diagnostics reported revenue of $70M and EBITDA of $17M.

EKF Diagnostics is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of 25%, and net margin of 4%.

See analyst estimates for EKF Diagnostics
LTMLast FY202320242025202620272028
Revenue$71M$70M$71M$68M$70M
Gross Profit$36M$36M$32M$33M$36M
Gross Margin52%51%45%48%51%
EBITDA$17M$17M$10M$15M$17M
EBITDA Margin24%25%15%22%25%
EBIT Margin16%16%8%13%14%
Net Profit$5M$3M$3M$8M$3M
Net Margin7%4%4%12%4%

Financial data powered by Morningstar, Inc.

EKF Diagnostics Stock Performance

EKF Diagnostics has current market cap of $151M, and enterprise value of $134M.

Market Cap Evolution


EKF Diagnostics' stock price is $0.35.

EKF Diagnostics share price decreased by 2.8% in the last 30 days, and increased by 4.8% in the last year.

EKF Diagnostics has an EPS (earnings per share) of $0.01.

See more trading valuation data for EKF Diagnostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$134M$151M-2.6%-2.8%-0.0%4.8%$0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

EKF Diagnostics Valuation Multiples

EKF Diagnostics trades at 1.9x EV/Revenue multiple, and 7.8x EV/EBITDA.

See NTM and 2027E valuation multiples for EKF Diagnostics

EV / Revenue (LTM)


EKF Diagnostics Financial Valuation Multiples

As of May 8, 2026, EKF Diagnostics has market cap of $151M and EV of $134M.

EKF Diagnostics has a P/E ratio of 31.0x.

LTMLast FY202320242025202620272028
EV/Revenue1.9x1.9x1.9x2.0x1.9x
EV/EBITDA7.8x7.8x12.9x8.9x7.8x
EV/EBIT11.5x12.3x22.8x15.7x14.2x
EV/Gross Profit3.7x3.7x4.1x4.1x3.7x
P/E31.0x52.3x47.2x17.8x52.3x
EV/FCF17.5x13.5x(148.7x)9.1x13.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified EKF Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

EKF Diagnostics Margins & Growth Rates

EKF Diagnostics grew revenue by 6% and EBITDA by 8% in the last fiscal year.

In the most recent fiscal year, EKF Diagnostics reported gross margin of 51%, EBITDA margin of 25%, and net margin of 4%.

See estimated margins and future growth rates for EKF Diagnostics

EKF Diagnostics Margins

Last FY202420252026202720282029
Gross Margin51%48%51%52%
EBITDA Margin25%22%25%25%
EBIT Margin16%13%14%18%
Net Margin4%12%4%12%
FCF Margin14%22%14%6%

EKF Diagnostics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%(5%)3%6%
Gross Profit Growth8%1%10%8%
EBITDA Growth8%45%13%8%
EBIT Growth21%45%11%39%
Net Profit Growth201%165%(66%)201%
FCF Growth(52%)(1742%)(33%)(52%)

Data powered by FactSet, Inc. and Morningstar, Inc.

EKF Diagnostics Operational KPIs

EKF Diagnostics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

EKF Diagnostics' Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EKF Diagnostics' Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for EKF Diagnostics
LTMLast FY202320242025202620272028
Rule of 4032%31%
Bessemer Rule of X43%40%
Revenue per Employee$0.2M
Opex per Employee$0.1M
G&A Expenses to Revenue28%38%37%36%38%
Opex to Revenue38%37%35%38%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EKF Diagnostics Competitors

EKF Diagnostics competitors include Biodesix, Neuronetics, Detection Technology, Airdoc, TeraView Holdings, Quanterix, BICO Group, Owlet, Aroa Biosurgery and JETEMA Co..

Most EKF Diagnostics public comparables operate across Medical Devices, Medical Imaging & Diagnostics, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Biodesix2.2x2.0x(11.3x)(13.1x)
Neuronetics1.4x1.4x(9.9x)(11.7x)
Detection Technology1.1x1.1x9.9x9.0x
Airdoc2.2x2.2x(58.6x)
TeraView Holdings
Quanterix0.5x0.5x(1.7x)(1.9x)
BICO Group0.8x0.8x67.3x32.2x
Owlet1.2x1.2x66.0x48.4x

This data is available for Pro users. Sign up to see all EKF Diagnostics competitors and their valuation data.

Start Free Trial

EKF Diagnostics M&A Activity

EKF Diagnostics has acquired 5 companies to date.

Last acquisition by EKF Diagnostics was on April 12th 2026. EKF Diagnostics acquired Beep Insights (technology assets) for $320M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by EKF Diagnostics

Beep Insights (technology assets)
ADL Health
DiaSpect Medical AB
Selah Genomics
Description
Beep Insights (Technology Assets) is a unit of Beep Insights.
ADL Health is a Houston-headquartered clinical laboratory certified under CLIA and CAP standards, specializing in PCR-based molecular diagnostics for infectious diseases. It processes tests for COVID-19, respiratory panels, and gastrointestinal pathogens using high-throughput Roche and Thermo Fisher systems. The lab handles 10,000 samples weekly, serving physicians, urgent cares, and employers across Texas. ADL Health provides rapid turnaround times of 24-48 hours and integrates with EHR systems like Epic. Founded in 2020 amid the pandemic, it expanded to wastewater surveillance for municipalities.
Selah Genomics is a clinical diagnostics company based in Austin, Texas, providing molecular and genomic testing services to healthcare providers and pharmaceutical firms. The laboratory supports Phase I-III clinical trials with companion diagnostics and pharmacogenomic panels, processing 50,000+ samples annually. Selah Genomics aids drug development for oncology and rare diseases, partnering with institutions like MD Anderson Cancer Center to improve patient monitoring and outcomes.
HQ CountryUnited StatesSwedenUnited States
HQ City
Greenville, SC
Deal Date12 Apr 202619 Nov 202124 Apr 201420 Mar 2014
Valuation$320Mundisclosed$17M$40M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all EKF Diagnostics acquisitions and their M&A valuation multiples.

Start Free Trial

EKF Diagnostics Investment Activity

EKF Diagnostics has invested in 1 company to date.

Latest investment by EKF Diagnostics was on August 20th 2020. EKF Diagnostics invested in Trellus Health in their $5M Seed round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by EKF Diagnostics

Trellus Health
Description
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
HQ CountryUnited Kingdom
HQ City
New York City, NY
Deal Date20 Aug 2020
RoundSeed
Raised$5M
InvestorsEKF Diagnostics; Mount Sinai Health System
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all EKF Diagnostics investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About EKF Diagnostics

When was EKF Diagnostics founded?EKF Diagnostics was founded in 2002.
Where is EKF Diagnostics headquartered?EKF Diagnostics is headquartered in United Kingdom.
How many employees does EKF Diagnostics have?As of today, EKF Diagnostics has over 303 employees.
Who is the CEO of EKF Diagnostics?EKF Diagnostics' CEO is Gavin Joseph Jones.
Is EKF Diagnostics publicly listed?Yes, EKF Diagnostics is a public company listed on London Stock Exchange.
What is the stock symbol of EKF Diagnostics?EKF Diagnostics trades under EKF ticker.
When did EKF Diagnostics go public?EKF Diagnostics went public in 2002.
Who are competitors of EKF Diagnostics?EKF Diagnostics main competitors include Biodesix, Neuronetics, Detection Technology, Airdoc, TeraView Holdings, Quanterix, BICO Group, Owlet, Aroa Biosurgery, JETEMA Co..
What is the current market cap of EKF Diagnostics?EKF Diagnostics' current market cap is $151M.
What is the current revenue of EKF Diagnostics?EKF Diagnostics' last 12 months revenue is $71M.
What is the current revenue growth of EKF Diagnostics?EKF Diagnostics revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of EKF Diagnostics?Current revenue multiple of EKF Diagnostics is 1.9x.
Is EKF Diagnostics profitable?Yes, EKF Diagnostics is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of EKF Diagnostics?EKF Diagnostics' last 12 months EBITDA is $17M.
What is EKF Diagnostics' EBITDA margin?EKF Diagnostics' last 12 months EBITDA margin is 24%.
What is the current EV/EBITDA multiple of EKF Diagnostics?Current EBITDA multiple of EKF Diagnostics is 7.8x.
What is the current FCF of EKF Diagnostics?EKF Diagnostics' last 12 months FCF is $8M.
What is EKF Diagnostics' FCF margin?EKF Diagnostics' last 12 months FCF margin is 11%.
What is the current EV/FCF multiple of EKF Diagnostics?Current FCF multiple of EKF Diagnostics is 17.5x.
How many companies EKF Diagnostics has acquired to date?As of May 2026, EKF Diagnostics has acquired 5 companies.
What was the largest acquisition by EKF Diagnostics?$320M acquisition of Beep Insights (technology assets) on 12th April 2026 was the largest M&A EKF Diagnostics has done to date.
What companies EKF Diagnostics acquired?EKF Diagnostics acquired Beep Insights (technology assets), Selah Genomics, DiaSpect Medical AB, Separation Technology, and ADL Health.
In how many companies EKF Diagnostics has invested to date?As of May 2026, EKF Diagnostics has invested in 1 company.
What was the last EKF Diagnostics investment?On 20th August 2020 EKF Diagnostics invested in Trellus Health, participating in a $5M Seed round, alongside Mount Sinai Health System.
In what companies EKF Diagnostics invested in?EKF Diagnostics invested in Trellus Health.

See public comps similar to EKF Diagnostics

Lists including EKF Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial